{"a":[{"_":"Priovant pushes ex-Pfizer asset across FDA finish line in rare skin and muscle disease","$":{"href":"/pharma/priovant-pushes-ex-pfizer-asset-across-fda-finish-line-rare-skin-and-muscle-disease","hreflang":"en"}}]}
RegulatoryapprovedPositive
AI Analysis
Summary
Priovant Therapeutics, backed by Roivant, has obtained FDA approval for its dual TYK2/JAK1 inhibitor in a rare skin and muscle disease, marking the ex-Pfizer asset's first regulatory approval.
Outcome Details
FDA approval for rare skin disease
Importance:8/10
Sentiment:
0.80
FDA approvalrare diseaseJAK inhibitorTYK2 inhibitorfirst approval
Related Companies
Read the original article
Published by FiercePharma on August 27, 2026 5:38 PM